China’s Strongest Pharmas Likely To Thrive Through Innovation And Acquisition Despite Global Crisis
This article was originally published in The Pink Sheet Daily
Analysts predict the country’s top 100 pharmas will collectively post a rise in operating profit of more than 20 percent in 2009.
You may also be interested in...
SHANGHAI - China will invest RMB 6.6 billion ($960 million) to launch a massive new drug development and manufacturing program from 2008 to 2010. Roughly 3,290 projects focused on preclinical studies and identifying new candidates are awaiting approval to initiate in 2009
BEIJING - China's new plan to inject RMB 4 trillion into the economy to stimulate growth and counter the effects of the global financial crisis will boost the overall health care sector and propel medical system reforms, according to analysts
China’s Health System Reforms Set To Spark Hospital Construction Boom And Boost Medical Device Makers
[Editor's note: This is part two in a new series on China's wide-ranging plans to reform the country's health system, including its hospitals, insurance schemes and access to medicines. Part one appeared in PharmAsia News on Oct. 30, 2008.]